The Amgen-backed biotech company, which has signed a lucrative research deal with Pfizer, is now looking to complement it with venture financing.
US-based biomedical research company Theraclone revealed in an interview on Tuesday that it is currently looking to raise about $10m in venture funding. The interview was conducted by biotechnology web monitor FierceBiotech, which named Theraclone, backed by US-based biotechnology company Amgen, one of its ‘Fierce 15′ most promising biotechnology companies.
Theraclone signed a collaboration pact with US-based pharmaceutical conglomerate Pfizer in January to develop treatments for HIV patients based on antibody research. The deal could be worth up to $632m…
